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Unit, Institute of Biomedical Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UKSummary regenerative effects, suggesting that the choice of therapeutic cellThere is an increasing range of potential applications of stem cells
in liver diseases, with many clinical studies already undertaken.
We identify four of the main areas which we propose stem cell
therapy could be a realistic aim for in the future: (1) to improve
regeneration and reduce scarring in liver cirrhosis by modulating
the liver’s own regenerative processes, (2) to down-regulate
immune mediated liver damage, (3) supplying hepatocyte-like
cells (HLCs) derived from stem cells for use in extracorporeal bio-
artiﬁcial liver machines, and (4) to use stem cell derived HLCs for
cell transplantation to supplement or replace hepatocyte function.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Whilst there have been advances in our understanding of the role
of stem cells in liver damage and repair as well as encouraging
results using stem cells as cell therapy in pre-clinical animal
models, the precise mode of action and optimal cell usage has
not been completely deﬁned. Moreover, clarity is required as to
what effects are needed in different types and severity of liver
disease (Fig. 1). Nonetheless, clinical trials of autologous cell ther-
apy for liver disease have begun. Small scale cell therapy studies
with autologous adult stem cells have demonstrated safety and
suggested possible beneﬁt [1]. This has driven the development
of larger studies to more rigorously test these observations. It is
clear that stem cells and their progeny have a variety of putative
functional roles, requiring careful thought as to what biological
action is intended after their infusion. For example, mesenchymal
stem cells (MSCs) have immunomodulatory capacity and cells of
the haematopoietic lineage may have anti-ﬁbrotic and pro-Journal of Hepatology 20
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required therapeutic effect may be very different.Stem cells for the treatment of liver disease
The mismatch between the number of patients requiring trans-
plantation for end stage liver disease and the number of available
organs is set to grow, highlighting the need to develop new strate-
gies to stimulate liver regeneration and reduce liver scarring.
Recent work suggests that these two aims are inextricably linked,
and that reducinghepaticﬁbrosis can result in activationof hepatic
progenitor cells (HPCs) resulting in parenchymal regeneration [2].
Degradation of excess liver scar is thus a suitable target for
cell therapy, and in this regard, Sakaida et al. have shown in a
mouse model of liver ﬁbrosis that autologous bone marrow cells
(BMCs) injected via the tail vein can engraft the liver and are able
to reduce liver scarring as well as stimulating this regenerative
process [3]. In these studies, it was suggested that murine Liv8
non-haematopoietic cells were responsible for this effect [3],
although the identity of these cells is not entirely clear. Further-
more, deﬁning the exact nature of these cells in the human set-
ting would be important to develop this approach as a human
therapy. More compelling evidence for the action of human hae-
matopoietic stem cells (HSCs) comes from their use in patients
with liver cancer (mainly metastasis) and otherwise normal liver
parenchyma [4]. Furst et al. included patients for whom [4] resec-
tion of the liver cancer was not possible at the outset as the resid-
ual liver volume would be insufﬁcient for the patient to survive.
Autologous bone marrow CD133+ cells were selectively infused
into the non-occluded segments II and III portal branches 2–4 h
after portal vein branch embolisation (I, IV, V–VIII); to see if this
would stimulate liver regeneration thus allowing earlier resec-
tion of the tumour. Liver volume increased much quicker in
patients that received stem cells, such that cancer resection could
be undertaken much sooner (27 days ± 11 vs. 45 days ± 21, p =
0.6). It should be noted however that this was a small study
and whilst there was a control arm it was not a randomised trial,
and importantly none of the patients had intrinsic liver disease.
Furthermore, as with many human studies, the mechanism of
action was not explored.
Macrophages, cells of haematopoietic origin, are known to
play a critical role in regulating liver ﬁbrosis in murine models
[5]. A single intraportal administration of macrophages has12 vol. 56 j 496–499
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Fig. 1. Requirements for different types of liver injury. This ﬁgure illustrates
the requirements that exist in differing types of liver injury.
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Fig. 2. Tailoring cell therapy. This ﬁgure suggests possible tailored cell therapy
options for the major types of liver disease.
JOURNAL OF HEPATOLOGYrecently been shown to reduce ﬁbrosis in a murine model of liver
injury and increase regeneration [6]. Interestingly, the macro-
phages may have both direct and indirect effects upon the dam-
aged liver as cell administration triggered the recruitment of
endogenous inﬂammatory cells to hepatic scar areas and poten-
tially ampliﬁed the donor cell effect [6]. This ‘‘cell ampliﬁcation
effect’’ does hold promise for clinical cell therapy where donor
cell numbers may be limited. Epithelial progenitor cells have also
been used successfully to reduce ﬁbrosis in a rodent model of
liver cirrhosis, however, it may be difﬁcult clinically to isolate a
source of endothelial progenitor cells for this purpose in humans
[7].
There is some concern regarding the use of autologous
unsorted BMCs as an injectable ‘‘therapy’’ for liver cirrhosis as
the BMCs contain MSCs, cells that can differentiate into
myoﬁbroblasts, the scar forming cells of the liver [8] in certain
settings. Of note, recent data showed that use of whole bone mar-
row as cell therapy in a rodent model of chronic liver injury leads
to a worsening of liver ﬁbrosis [6]. Uncontrolled clinical studies
using infusions of unsorted autologous BM-derived mononuclear
cells infusions for liver cirrhosis have been reported to show a
reduction in Child’s Pugh score and liver scarring and increased
hepatocyte proliferation [9]. This may reﬂect the absence of stro-
mal cells in mononuclear cell preparations, but also highlights
the possibility that there may be differences between human
and murine responses to cell therapy. This will be challenging
as use of novel cell populations or combinations in patients will
generally be informed by rodent studies.
MSCs have been reported to contribute to the direct produc-
tion of new hepatocytes as well as to stimulate proliferation of
endogenous hepatocytes [10,11], although this is not a universal
ﬁnding [12]. Furthermore, the description of such ‘‘hepatocyte-
like cells‘‘ is often incomplete, and does not as yet represent their
adoption of a majority of a hepatocyte’s complex phenotype by
the MSC or their progeny [13]. To demonstrate that a MSC (or
other stem cell) had differentiated into a hepatocyte would
require the demonstration of hepatocytic functionality in vitro
and in vivo for robust conﬁrmation. It is therefore possible that
much of the impact of injected MSCs in liver injury models
may not relate to their adoption of a hepatocyte phenotype, but
through other mechanisms. The immunomodulatory properties
of MSCs have been demonstrated in a range of rodent modelsJournal of Hepatology 201of non-hepatic [14] and hepatic [15] immune-mediated injury,
as well as clinical studies in patients with GVHD who have hepa-
tic damage where clinical beneﬁt is reported [16]. Protocols for
the isolation and characterisation of MSCs are evolving, and it
is likely that there are different functional sub-sets which may
mediate anti- and pro-inﬂammatory actions [17]. Despite this
ambiguity regarding the function of MSCs in the literature there
have been clinical studies reported suggesting that cell therapy
with MSCs for liver cirrhosis can be beneﬁcial but it is important
to note that these studies are small and uncontrolled so whilst
interesting should be interpreted with caution [18].
Of the clinical studies published, the overwhelming data sug-
gests stem cell therapy is safe [1], although there are possible
concerns regarding the route of delivery of cell therapy. Whilst
no studies report superior outcomes when cells are directly
injected into the liver (portal vein or hepatic artery), there have
been complications such as hepatic artery dissection [19] and
increased portal hypertensive bleeding [20] following this
approach. Furthermore, the intravenous administration of autol-
ogous BM mononuclear cells resulted in hepatic homing of the
injected cells suggesting this easier, safer route may be an ade-
quate option for cell delivery [9,21]. Assuming that delivery to
the liver is important for stem cell infusions to exert their optimal
effect, then developing a better understanding of the mechanisms
regulating their hepatic ingress may allow for further improve-
ments to treatment protocols.
Whilst patients with a wide range of disease severity have
been included in clinical trials, the priority remains to irrefutably
conﬁrm the efﬁcacy of cell/stem cell therapy. In this regard,
choosing patients in which the beneﬁt may be most reliably
determined and of greatest value is important. Patients verging
on the cusp of requiring a liver transplant (e.g. with MELD score
approaching/just below 15) are good candidates as even a small
percentage improvement in liver function may be sufﬁcient to
signiﬁcantly delay or indeed remove altogether the need for liver
transplant.
For patients with cirrhosis/advanced ﬁbrosis, the data at pres-
ent would support further studies with macrophages, HSCs and
BM mononuclear cells, whereas the immunomodulatory/anti-
inﬂammatory properties of MSCs require further conﬁrmation
in immune-mediated models of liver injury. Further data may
allow for the tailoring of cell therapy towards speciﬁc types of
liver injury (Fig. 2).2 vol. 56 j 496–499 497
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Stem cells as a source of hepatocyte like cells
There have been many reports that various adult stem cells have
the capacity to differentiate into hepatocyte like cells, although
most of these studies incompletely characterise the stem cell
derived hepatocytes ‘‘hepatocytic functions’’ or do not demon-
strate in vivo functionality to the same extent as endogenous
hepatocytes [13]. Whilst there are examples of ‘‘hepatocyte-like
cells’’ produced from non-hepatic adult stem cells [22], it is our
view, however, that this is unlikely to be a signiﬁcant source of
new hepatocytes that are of sufﬁcient functionality to be clini-
cally relevant. The liver’s own HPCs are a realistic potential
source of hepatocytes, however thus far it has proven difﬁcult
to isolate and expand these cells from the human liver and then
control their differentiation into hepatocytes of sufﬁcient number
and quality. Indeed, the liver’s own HPCs may be best targeted
in situ via cell therapy, drugs or other such small molecule
approaches.
Embryonic stem cells have the advantage of being able to pro-
liferate in an unlimited fashion and produce large numbers of
HLCs in both mouse and man settings [23]. In vitro, these cells
have been shown to have reasonable functional capacity,
although there is still caution about their use for transplantation
due to their propensity to form both malignant and non-malig-
nant tumours. Further work is required to reduce this risk, which
may involve more deﬁnitive hepatocytic differentiation of HLCs,
use of highly sorted populations to exclude contaminating cells
and incorporation of clinically approved suicide genes (http://
www.lentigen.com/products/lg690). In addition, there are ethical
issues regarding the use of human embryonic stem cells, which
will always have implications for their clinical use.
A recent development allows for the production of similar
cells, induced pluripotent stem cells (iPSCs), by over-expressing
transcription factors such as SOX2 and Oct4 in adult somatic
cells. Keratinocytes isolated from skin biopsies have been used
as a starting cell population to produce these iPSCs. This technol-
ogy has great potential for disease modelling as the cells can be
readily obtained from patients with metabolic diseases, and the
derived cells are likely to exhibit metabolic defects, thus allowing
the development of ‘‘liver disease in a dish’’ studies [24]. Hepato-
cytes derived from iPS cells have reasonable synthetic and meta-
bolic capacity [25], and seem to be similar to cells derived from
ES cells [26,27]. However, the same concerns remain about their
use in a transplant setting, as we cannot yet be certain that these
cells would not undergo reversion to more primitive state with
uncontrolled expansion within the recipient.Conclusions
Cell therapy is an exciting but challenging frontier in Hepatology,
offering the potential for a range of new therapeutic interven-
tions. This reinforces the need to develop strategies to improve
liver regeneration. In this regard, cells which modulate liver
ﬁbrosis, or which act directly on the liver’s own HPC population
seem likely candidates as do small molecules and drugs. In addi-
tion, iPSCs are excellent candidates for the production of HLCs
although there is caution about their in vivo use until long term
data has shown that these cells can behave in an appropriate
homoeostatic manner and not develop into tumours.498 Journal of Hepatology 201Conﬂict of interest
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